Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Novacyt ( (FR:ALNOV) ) just unveiled an update.
Novacyt S.A. reported its unaudited interim results for the first half of 2025, showing a period of consolidation aimed at long-term growth. The company achieved a 2% revenue increase, excluding the impact of a divestment, and saw strong demand in the reproductive health segment, particularly in the APAC region. The company launched the LightBench® Discover instrument for genomic research labs and received EU accreditation for key assays. Despite a slight decline in overall revenue, Novacyt reduced its EBITDA loss and maintained a strong cash position, positioning itself for future profitability and growth.
More about Novacyt
Novacyt is an international molecular diagnostics company that offers a wide range of integrated technologies and services, primarily focusing on genomic medicine. The company develops, manufactures, and commercializes molecular assays and instrumentation to provide end-to-end solutions across sectors such as human health, animal health, and environmental. Novacyt operates in three business segments: Clinical, Instrumentation, and Research Use Only, and is headquartered in France with offices in the UK, Singapore, the US, and Canada.
Learn more about ALNOV stock on TipRanks’ Stock Analysis page.